Last reviewed · How we verify
LMN-201 Anti-toxin B VHH-2 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LMN-201 Anti-toxin B VHH-2 (LMN-201 Anti-toxin B VHH-2) — Lumen Bioscience, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LMN-201 Anti-toxin B VHH-2 TARGET | LMN-201 Anti-toxin B VHH-2 | Lumen Bioscience, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LMN-201 Anti-toxin B VHH-2 CI watch — RSS
- LMN-201 Anti-toxin B VHH-2 CI watch — Atom
- LMN-201 Anti-toxin B VHH-2 CI watch — JSON
- LMN-201 Anti-toxin B VHH-2 alone — RSS
Cite this brief
Drug Landscape (2026). LMN-201 Anti-toxin B VHH-2 — Competitive Intelligence Brief. https://druglandscape.com/ci/lmn-201-anti-toxin-b-vhh-2. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab